Swedish Orphan Biovitrum stock rises following Q1 revenue beat

Published 29/04/2025, 09:38
Swedish Orphan Biovitrum stock rises following Q1 revenue beat

Investing.com -- Swedish Orphan Biovitrum shares climbed 3% as the company reported a first-quarter revenue of SEK 6.45 billion marking a 3% increase YoY and surpassing consensus expectations by the same margin.

The uptick in the stock comes on the back of stronger-than-expected sales from its Haemophilia portfolio and robust performance from Gamifant, which more than made up for the underperformance of Vonjo due to stocking issues and Medicare Part D reform impact in the U.S., as well as lower Beyfortus royalty and Synagis sales.

Despite the challenges faced by some products, the company’s adjusted EBITA reached SEK 2.35 billion, boasting a 36.4% margin, which was 14% higher than consensus. Net income also exceeded expectations, coming in at SEK 875 million, 17% above consensus.

The company has maintained its full-year guidance, expecting high single-digit sales growth YoY and an adjusted EBITA margin in the mid-30% range.

Analysts at RBC commented on the results, stating, "We think this will be taken positively, particularly given that consensus expectations had dropped considerably in recent weeks on expectations of weaker RSV sales and profits."

The positive results were partly attributed to the fact that, excluding the RSV products and discontinued ReFacto manufacturing sales, group sales were up a notable 23% at constant exchange rates (CER).

Additionally, the seasonal shift in U.S. Beyfortus supply for Q1 vaccinations, which was largely shipped in the fourth quarter of the previous year, did not impact the company’s annual expectations for Beyfortus royalties.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.